337 related articles for article (PubMed ID: 34059837)
1. A primer on medicinal cannabis safety and potential adverse effects.
Arnold JC
Aust J Gen Pract; 2021 Jun; 50(6):345-350. PubMed ID: 34059837
[TBL] [Abstract][Full Text] [Related]
2. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
4. Medicinal cannabis for the treatment of anxiety disorders.
Berger M; Amminger GP; McGregor IS
Aust J Gen Pract; 2022 Aug; 51(8):586-592. PubMed ID: 35908759
[TBL] [Abstract][Full Text] [Related]
5. Medicinal cannabis for patients with chronic non-cancer pain: analysis of safety and concomitant medications.
Schubert EA; Alffenaar JC; Johnstone MT; Barlow JW; Wheate NJ
Int J Pharm Pract; 2023 Mar; 31(1):70-79. PubMed ID: 36445409
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of self-directed medical cannabis treatment for pain.
Li X; Vigil JM; Stith SS; Brockelman F; Keeling K; Hall B
Complement Ther Med; 2019 Oct; 46():123-130. PubMed ID: 31519268
[TBL] [Abstract][Full Text] [Related]
8. Medical cannabis and driving.
Arkell TR; McCartney D; McGregor IS
Aust J Gen Pract; 2021 Jun; 50(6):357-362. PubMed ID: 34059836
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
10. Mapping cannabis potency in medical and recreational programs in the United States.
Cash MC; Cunnane K; Fan C; Romero-Sandoval EA
PLoS One; 2020; 15(3):e0230167. PubMed ID: 32214334
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.
S G; Hb S; K L; R T; Bs R; Ps S; F S; Ab O
Mult Scler Relat Disord; 2021 Feb; 48():102708. PubMed ID: 33387864
[TBL] [Abstract][Full Text] [Related]
12. Emergent Medical Illnesses Related to Cannabis Use.
Randall K; Hayward K
Mo Med; 2019; 116(3):226-228. PubMed ID: 31527946
[TBL] [Abstract][Full Text] [Related]
13. Place of therapeutic cannabis in France and safety data: A literature review.
Corso B; Bacle A; Demay E; Mercerolle M; Pelletier R; Gicquel T; Le Daré B
Ann Pharm Fr; 2023 Jun; 81(4):583-595. PubMed ID: 36841395
[TBL] [Abstract][Full Text] [Related]
14. Medicinal cannabis in the treatment of chronic pain.
Henderson LA; Kotsirilos V; Cairns EA; Ramachandran A; Peck CC; McGregor IS
Aust J Gen Pract; 2021 Oct; 50(10):724-732. PubMed ID: 34590094
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
[TBL] [Abstract][Full Text] [Related]
16. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
Szaflarski JP; Bebin EM
Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
[TBL] [Abstract][Full Text] [Related]
17. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population.
Highet BH; Lesser ER; Johnson PW; Kaur JS
Am J Hosp Palliat Care; 2020 Aug; 37(8):589-593. PubMed ID: 31986898
[TBL] [Abstract][Full Text] [Related]
19. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.
Niesink RJ; Rigter S; Koeter MW; Brunt TM
Addiction; 2015 Dec; 110(12):1941-50. PubMed ID: 26234170
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of Medical Cannabis.
Amin MR; Ali DW
Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
